SterisSTE 90 5-Year Yield-on-Cost % is 1.86 as of Jul. 11, 2026, which is 24% above its 10-year median of 1.50. GuruFocus rates STE with a GF Score™ of 90/100 and a GF Value™ of $269.58 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 327 Medical Devices & Instruments companies, Steris ranks worse than 55.96% on this metric.
Steris's yield on cost for the quarter that ended in Mar. 2026 was 1.86.
The historical rank and industry rank for Steris's 5-Year Yield-on-Cost % or its related term are showing as below:
STE'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.07 Med: 1.5 Max: 2.5
Current: 1.86
During the past 13 years, Steris's highest Yield on Cost was 2.50. The lowest was 1.07. And the median was 1.50.
STE's 5-Year Yield-on-Cost % is ranked worse than 55.96% of 327
companies
in the Medical Devices & Instruments industry
Industry Median: 2.34
vs STE: 1.86
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Steris 5-Year Yield-on-Cost % Related Terms
STE vs ZBH, DXCM, PEN: 5-Year Yield-on-Cost % Comparison
For the Medical Devices subindustry, Steris's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Steris 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Steris's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Steris's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Steris is calculated as
Steris (STE) has a 5-Year Yield-on-Cost % of 1.86 as of Jul. 11, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Steris and its competitors. This is 24% above median its historical median of 1.50. Over the past decade, Steris' 5-Year Yield-on-Cost % has ranged from 1.07 to 2.50. According to the industry distribution chart, Steris ranks #183 out of 327 companies in the Medical Devices & Instruments industry, placing it in the top 56%.
Is Steris' 5-Year Yield-on-Cost % too high?
Steris' current 5-Year Yield-on-Cost % of 1.86 is 24% above median its 10-year median of 1.50. Over the past 10 years, this metric has ranged from a low of 1.07 to a high of 2.50. The Medical Devices & Instruments industry median 5-Year Yield-on-Cost % is 2.34. Steris' value of 1.86 is 20.5% below this industry median. Based on the distribution chart, Steris ranks #183 out of 327 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Steris has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Steris' 5-Year Yield-on-Cost % compare to ZBH and DXCM?
According to the Medical Devices & Instruments industry distribution chart, Steris ranks #183 out of 327 companies for 5-Year Yield-on-Cost %. This places Steris in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.34. Steris' value of 1.86 is 20.5% below this benchmark. Historically, Steris' own 5-Year Yield-on-Cost % has ranged from 1.07 to 2.50 over the past decade. While the company's 10-year median is 1.50 vs. the industry median of 2.34, Steris has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.34, based on 327 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Steris's current 5-Year Yield-on-Cost % of 1.86 is 20.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Steris and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Steris's current 5-Year Yield-on-Cost % is 1.86, which is 24% above median its own 10-year median of 1.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Steris stock overvalued right now?
Based on GuruFocus' analysis, Steris (STE) is currently considered Modestly Undervalued. The stock's GF Value™ is $269.58, compared to a current price of $216.00 — trading 19.9% below its estimated fair value. The current 5-Year Yield-on-Cost % is 1.86, which is 24% above median its 10-year median of 1.50 and 20.5% below the Medical Devices & Instruments industry median of 2.34. Steris' overall GF Score™ is 90/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Steris (STE), the current 5-Year Yield-on-Cost % is 1.86 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Steris (STE) Overvalued in 2026?
Based on GuruFocus' analysis, Steris stock appears to be undervalued.
The current stock price of $216.00 is trading 19.9% below its estimated GF Value™ of $269.58.
GuruFocus considers Steris to be Modestly Undervalued.
Key valuation signals for STE:
5-Year Yield-on-Cost %: 1.86 (24% above median its 10-year median of 1.50)
GF Value™: $269.58 vs. price of $216.00 (19.9% below fair value)
Industry Position: 20.5% below the Medical Devices & Instruments median (#183 of 327)
No single metric tells the full story. See the STE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Steris also sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 20% from Applied Sterilization Technologies, or AST, and 10% from life sciences services after the divestment of its dental products business.
90GF Score
Get the complete analysis for STE
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STE has been successfully added to your 